Related Experiment Video
Updated: Jul 5, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Response evaluation of gastrointestinal stromal tumors
1University of Texas, MD Anderson Cancer Center, Houston Texas 77030, USA. hchoi@di.mdacc.tmc.edu
Abstract:
Clinical management of patients with gastrointestinal stromal tumors (GISTs) has dramatically changed with the introduction of novel therapeutics, such as imatinib mesylate. This has created a need to re-evaluate the existing criteria used to assess treatment response. The current Response Evaluation Criteria in Solid Tumors are based on unidimensional tumor size, and do not take into account changes in responding GISTs such as a decrease in tumor density and decrease in the number of intratumoral vessels with computed tomography (CT). Positron emission tomography (PET) has been found to be highly sensitive in detecting early response, and to be useful in predicting long-term response to imatinib in patients with metastatic GIST; however, widespread use of PET is limited because of a lack of scanner availability and cost constraints. Modified CT criteria using a combination of tumor density and tumor size are promising in early response evaluation, and have excellent prognostic value. Identifying appropriate treatment response criteria is essential to optimize treatment for patients with GIST.
Insights
New criteria evaluating tumor density and size on CT scans show promise for assessing treatment response in gastrointestinal stromal tumors (GISTs). These modified criteria offer better prognostic value than current methods for GIST patients.
Area of Science:
- Oncology
- Radiology
- Medical Imaging
Background:
- Novel therapeutics like imatinib mesylate have transformed gastrointestinal stromal tumor (GIST) management.
- Existing Response Evaluation Criteria in Solid Tumors (RECIST) rely solely on unidimensional tumor size.
- RECIST does not account for specific GIST treatment response indicators like decreased tumor density or intratumoral vascularity on CT scans.
Purpose of the Study:
- To re-evaluate current criteria for assessing treatment response in GIST patients.
- To explore the utility of modified computed tomography (CT) criteria incorporating tumor density and size.
- To determine if these modified CT criteria can effectively predict long-term response and prognosis.
Main Methods:
- Review of current Response Evaluation Criteria in Solid Tumors (RECIST).
- Evaluation of positron emission tomography (PET) for early response detection in metastatic GIST.
- Assessment of modified CT criteria combining tumor density and size for response evaluation.
Main Results:
- Positron emission tomography (PET) is sensitive for early response detection and predicting long-term imatinib response in metastatic GIST, but faces accessibility and cost limitations.
- Modified CT criteria, integrating tumor density and size, demonstrate promise for early response evaluation in GIST.
- These modified CT criteria exhibit excellent prognostic value for GIST patients.
Conclusions:
- Current RECIST criteria are insufficient for evaluating treatment response in GIST patients receiving novel therapies.
- Modified CT criteria incorporating tumor density and size offer a promising, accessible alternative for assessing GIST treatment response and prognosis.
- Optimizing treatment response criteria is crucial for improving patient outcomes in GIST management.
